0ABR.LSE

H. Lundbeck A/S

0ABR.LSE, UK

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. a strategic. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.

https://www.lundbeck.com

Stock Price

DKK0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.16

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Low

1.50

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

4.38 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.07 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

33.89 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.11

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of H. Lundbeck A/S

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

—

EPS Actual

—

EPS Estimate

—

EPS Difference

—

Surprise Percent

undefined%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(7.3)
GARP
Fair GARP(5.5)
Growth
Moderate Growth(4)
Momentum
Moderate Momentum(4)
Net Net
Possible Net-Net(3.5)
Quality
Moderate Quality(5.5)
Value
Undervalued(8.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

DKK 0

Cost Of Revenue

DKK 0

Gross Profit

DKK 0

Operating Expenses

DKK 0

Operating Income

DKK 0

Interest Expense

DKK 0

Pretax Income

DKK 0

Net Income

DKK 0

Income Tax Expense

DKK 0

EBITDA

DKK 0

Total Other Income Expense Net

DKK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

DKK 0

Short Term Investments

DKK 0

Receivables

DKK 0

Inventories

DKK 0

Total Current Assets

DKK 0

Property Plant Equipment

DKK 0

Total Assets

DKK 0

Payables

DKK 0

Short Term Debt

DKK 0

Long Term Debt

DKK 0

Total Liabilities

DKK 0

Equity

DKK 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

DKK 0

Depreciation

DKK 0

Change In Working Capital

DKK 0

Cash From Operations

DKK 0

Capital Expenditures

DKK 0

Cash From Investing

DKK 0

Cash From Financing

DKK 0

Net Change In Cash

DKK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.